Celldex Therapeutics’ (CLDX) Buy Rating Reaffirmed at HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $80.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 221.16% from the company’s current price.

A number of other equities research analysts also recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Finally, Citigroup assumed coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $62.25.

Celldex Therapeutics Stock Performance

NASDAQ CLDX traded up $0.09 on Thursday, reaching $24.91. The stock had a trading volume of 272,682 shares, compared to its average volume of 884,046. The business’s 50-day moving average price is $27.00 and its 200 day moving average price is $33.47. The stock has a market cap of $1.65 billion, a P/E ratio of -9.69 and a beta of 1.57. Celldex Therapeutics has a 12-month low of $22.93 and a 12-month high of $53.18.

Insider Buying and Selling

In other Celldex Therapeutics news, CEO Anthony S. Marucci acquired 11,500 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was purchased at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. KBC Group NV lifted its holdings in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Celldex Therapeutics during the second quarter valued at $76,000. Los Angeles Capital Management LLC grew its position in shares of Celldex Therapeutics by 9.5% during the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 638 shares during the last quarter. Quest Partners LLC lifted its position in Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 6,879 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in Celldex Therapeutics by 23.7% during the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after purchasing an additional 1,504 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.